Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol

Neuroendocrinology. 1984 May;38(5):407-10. doi: 10.1159/000123926.

Abstract

Mice were administered the dopaminergic antagonists haloperidol or domperidone in their drinking water for 2 or 21 days. Serum prolactin levels and striatal 3H-spiperone-binding sites (D-2 receptors) were compared to vehicle-treated controls. While only domperidone elevated serum prolactin levels, only haloperidol increased the density of striatal 3H-spiperone-binding site. The failure of domperidone, a potent D-2 receptor antagonist, to increase striatal receptor number is attributed to its poor penetration of the blood-brain barrier. These results indicate that peripheral effects of neuroleptic drugs, including prolactin elevation, are not sufficient for the development of dopaminergic supersensitivity in the central nervous system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Butyrophenones / metabolism*
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Domperidone / pharmacology*
  • Haloperidol / pharmacology*
  • Kinetics
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Prolactin / blood*
  • Receptors, Dopamine / drug effects*
  • Receptors, Dopamine / metabolism
  • Spiperone / metabolism*

Substances

  • Butyrophenones
  • Receptors, Dopamine
  • spiroperidol receptor
  • Spiperone
  • Domperidone
  • Prolactin
  • Haloperidol